Dantrolene Therapy for Inhibiting SARS-CoV Replication

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for effective treatments and methods to inhibit the replication, entry, maturation, and release of SARS-CoV viruses, as well as reduce their infectivity, in order to combat severe acute respiratory syndrome (SARS) caused by SARS-associated coronaviruses like SARS-CoV-1 and SARS-CoV-2.

Innovation Solution

Administering dantrolene or its pharmaceutically acceptable salts or prodrugs to subjects or host cells to inhibit SARS-CoV replication, entry, maturation, and release, thereby reducing viral infectivity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments are used for SARS, then treatment effectiveness is limited, but dantrolene administration provides effective viral replication inhibition and symptom improvement

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidavailability of effective treatments

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the pharmacological parameter by introducing dantrolene, a muscle relaxant with off-target antiviral effects, to treat SARS. This parameter change from conventional antivirals to a different drug class achieves effective viral replication inhibition and symptom improvement where conventional treatments failed

Inventive Principle:

Principle #35Parameter changes

2Productivity

If dantrolene is administered to inhibit SARS-CoV replication, then viral load decreases and clinical symptoms improve, but the mechanism of action requires further elucidation

Engineering Contradiction:

Improveviral replication inhibitionVSAvoidmechanism of action understanding

Core Design Contradiction:

ProductivityVSLoss of information

Solution Approach 1:

The patent employs multiple feedback mechanisms to elucidate the mechanism of action: (1) measuring viral load changes to confirm replication inhibition, (2) monitoring clinical symptoms (fever, oxygen saturation) to assess therapeutic effect, (3) using WHO Ordinal Scale and SOFA scores to evaluate disease severity reduction, and (4) conducting cellular studies to observe direct viral effects

Inventive Principle:

Principle #23Feedback

Data Source

PatentUS12582633B2Methods of treating severe acute respiratory syndrome

Publication Date: 2026.03.24 EAGLE PHARMACEUTICALS INC

AI summary

The disclosure is directed to methods of using dantrolene or a dantrolene prodrug, or a pharmaceutically acceptable salt thereof, to treat Severe Acute Respiratory Syndrome.